Compare Stocks: PHR, SDGR, GDRX, and CERT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$8.13 -3.2%	$7.80	$4.45 ▼ $13.88	$1.28B	1.4	1.86 million shs	3.91 million shs
GDRX GoodRx	$3.39 -2.9%	$3.36	$1.77 ▼ $5.81	$1.20B	1.59	1.40 million shs	721,565 shs
PHR Phreesia	$10.26 -0.9%	$11.20	$7.77 ▼ $25.00	$642.43M	0.86	717,575 shs	553,800 shs
SDGR Schrodinger	$23.93 +2.9%	$17.99	$10.94 ▼ $24.39	$1.72B	1.69	1.10 million shs	2.80 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	+5.00%	+8.53%	+5.00%	+39.30%	-25.13%
GDRX GoodRx	-1.97%	-0.85%	-6.43%	+33.72%	-14.46%
PHR Phreesia	-0.46%	+1.30%	-15.62%	+10.57%	-55.70%
SDGR Schrodinger	+12.05%	+16.08%	+32.18%	+49.71%	+25.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$8.13 -3.2%	$7.80	$4.45 ▼ $13.88	$1.28B	1.4	1.86 million shs	3.91 million shs
GDRX GoodRx	$3.39 -2.9%	$3.36	$1.77 ▼ $5.81	$1.20B	1.59	1.40 million shs	721,565 shs
PHR Phreesia	$10.26 -0.9%	$11.20	$7.77 ▼ $25.00	$642.43M	0.86	717,575 shs	553,800 shs
SDGR Schrodinger	$23.93 +2.9%	$17.99	$10.94 ▼ $24.39	$1.72B	1.69	1.10 million shs	2.80 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	+5.00%	+8.53%	+5.00%	+39.30%	-25.13%
GDRX GoodRx	-1.97%	-0.85%	-6.43%	+33.72%	-14.46%
PHR Phreesia	-0.46%	+1.30%	-15.62%	+10.57%	-55.70%
SDGR Schrodinger	+12.05%	+16.08%	+32.18%	+49.71%	+25.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERT Certara	2.45	Hold	$8.28	1.82% Upside
GDRX GoodRx	2.08	Hold	$4.23	24.70% Upside
PHR Phreesia	2.37	Hold	$14.00	36.52% Upside
SDGR Schrodinger	2.29	Hold	$20.50	-14.33% Downside

Current Analyst Ratings Breakdown

Latest PHR, SDGR, GDRX, and CERT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	PHR Phreesia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
9/4/2026	PHR Phreesia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/4/2026	PHR Phreesia	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $13.00
9/4/2026	PHR Phreesia	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$10.00 ➝ $11.00
9/4/2026	PHR Phreesia	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/3/2026	PHR Phreesia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$9.00 ➝ $10.00
9/3/2026	PHR Phreesia	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$19.00
9/3/2026	PHR Phreesia	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
8/31/2026	PHR Phreesia	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
8/27/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	GDRX GoodRx	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$3.00 ➝ $4.00

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERT Certara	$418.84M	2.96	$0.73 per share	11.10	$6.67 per share	1.22
GDRX GoodRx	$796.85M	1.46	$0.39 per share	8.72	$1.81 per share	1.87
PHR Phreesia	$480.59M	1.32	$0.74 per share	13.87	$5.99 per share	1.71
SDGR Schrodinger	$255.87M	6.90	N/A	N/A	$4.94 per share	4.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERT Certara	-$1.60M	-$0.45	N/A	29.04	N/A	-16.75%	3.86%	2.65%	11/5/2026 (Estimated)
GDRX GoodRx	$30.44M	$0.04	84.77	16.95	1.74	2.07%	7.22%	2.53%	11/3/2026 (Estimated)
PHR Phreesia	$2.31M	$0.17	60.33	13.86	N/A	2.06%	5.22%	3.02%	N/A
SDGR Schrodinger	-$103.26M	-$0.74	N/A	N/A	N/A	-20.98%	-16.37%	-8.19%	11/4/2026 (Estimated)

Latest PHR, SDGR, GDRX, and CERT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2027	PHR Phreesia	$0.0851	$0.03	-$0.0551	$0.03	$129.06 million	$129.46 million
8/5/2026	Q2 2026	GDRX GoodRx	$0.0797	$0.08	+$0.0003	$0.02	$193.23 million	$200.41 million
8/5/2026	Q2 2026	SDGR Schrodinger	-$0.4145	$0.08	+$0.4945	$0.08	$47.19 million	$58.89 million
8/4/2026	Q2 2026	CERT Certara	$0.0893	$0.08	-$0.0093	-$0.36	$98.09 million	$93.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERT Certara	N/A	N/A	N/A	N/A	N/A
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
PHR Phreesia	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERT Certara	0.30	2.55	2.55
GDRX GoodRx	0.74	1.38	1.38
PHR Phreesia	0.33	1.76	1.76
SDGR Schrodinger	N/A	2.71	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERT Certara	73.96%
GDRX GoodRx	63.77%
PHR Phreesia	92.10%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
CERT Certara	1.08%
GDRX GoodRx	5.87%
PHR Phreesia	5.20%
SDGR Schrodinger	10.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERT Certara	1,576	152.54 million	150.89 million	Optionable
GDRX GoodRx	697	342.57 million	322.47 million	Optionable
PHR Phreesia	1,789	62.07 million	58.84 million	Optionable
SDGR Schrodinger	850	73.82 million	66.37 million	Optionable

PHR, SDGR, GDRX, and CERT Headlines

Recent News About These Companies

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16 at 11:00 AM | seekingalpha.com

Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?

September 16 at 7:56 AM | zacks.com

Schrödinger jumps 12% to new 52-week high amid AI drug-discovery interest

September 15 at 8:54 PM | seekingalpha.com

Schrodinger (NASDAQ:SDGR) Sets New 12-Month High - Still a Buy?

September 15 at 2:39 PM | marketbeat.com

Schrodinger (NASDAQ:SDGR) Trading 9.7% Higher - Time to Buy?

September 14 at 3:39 PM | marketbeat.com

Squarepoint Ops LLC Buys 155,556 Shares of Schrodinger, Inc. $SDGR

September 13 at 4:15 AM | marketbeat.com

Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates

September 10, 2026 | finance.yahoo.com

Tectora Therapeutics inc. announced that it has received $55 million in funding from New Enterprise Associates, Inc., RA Capital Management, L.P., Schrödinger, Inc.

September 9, 2026 | marketscreener.comM

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

September 9, 2026 | finance.yahoo.com

Legal & General Group Plc Invests $2.29 Million in Schrodinger, Inc. $SDGR

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Schrodinger, Inc. $SDGR

September 5, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 438,798 Shares of Schrodinger, Inc. $SDGR

September 4, 2026 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Shares Down 4.5% - Here's Why

September 2, 2026 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Trading 4.6% Higher - Should You Buy?

September 1, 2026 | marketbeat.com

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

September 1, 2026 | businesswire.com

Beacon Pointe Advisors LLC Takes Position in Schrodinger, Inc. $SDGR

September 1, 2026 | marketbeat.com

Deutsche Bank AG Purchases Shares of 62,368 Schrodinger, Inc. $SDGR

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Makes New $3.18 Million Investment in Schrodinger, Inc. $SDGR

August 29, 2026 | marketbeat.com

BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGR

August 29, 2026 | marketbeat.com

Algert Global LLC Trims Stake in Schrodinger, Inc. $SDGR

August 28, 2026 | marketbeat.com

71,397 Shares in Schrodinger, Inc. $SDGR Bought by Ieq Capital LLC

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHR, SDGR, GDRX, and CERT Company Descriptions

Certara NASDAQ:CERT

$8.13 -0.27 (-3.21%)

Closing price 04:00 PM Eastern

Extended Trading

$8.38 +0.24 (+3.01%)

As of 07:58 PM Eastern

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

GoodRx NASDAQ:GDRX

$3.39 -0.10 (-2.87%)

Closing price 04:00 PM Eastern

Extended Trading

$3.39 0.00 (0.00%)

As of 07:53 PM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Phreesia NYSE:PHR

$10.26 -0.10 (-0.92%)

Closing price 03:59 PM Eastern

Extended Trading

$10.26 +0.01 (+0.10%)

As of 07:30 PM Eastern

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.

Schrodinger NASDAQ:SDGR

$23.93 +0.68 (+2.92%)

Closing price 04:00 PM Eastern

Extended Trading

$23.88 -0.05 (-0.23%)

As of 07:57 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHR, SDGR, GDRX, and CERT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHR, SDGR, GDRX, and CERT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHR, SDGR, GDRX, and CERT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHR, SDGR, GDRX, and CERT Company Descriptions

Certara NASDAQ:CERT

GoodRx NASDAQ:GDRX

Phreesia NYSE:PHR

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHR, SDGR, GDRX, and CERT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHR, SDGR, GDRX, and CERT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHR, SDGR, GDRX, and CERT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHR, SDGR, GDRX, and CERT Company Descriptions

Certara NASDAQ:CERT

GoodRx NASDAQ:GDRX

Phreesia NYSE:PHR

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools